GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (BSP:R1DY34) » Definitions » Cyclically Adjusted Revenue per Share

Dr Reddy's Laboratories (BSP:R1DY34) Cyclically Adjusted Revenue per Share : R$12.69 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Dr Reddy's Laboratories's adjusted revenue per share for the three months ended in Dec. 2023 was R$4.243. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$12.69 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Dr Reddy's Laboratories's average Cyclically Adjusted Revenue Growth Rate was 7.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Dr Reddy's Laboratories was 18.80% per year. The lowest was 5.80% per year. And the median was 8.50% per year.

As of today (2024-04-28), Dr Reddy's Laboratories's current stock price is R$62.64. Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was R$12.69. Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is 4.94.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.89. The lowest was 2.27. And the median was 3.94.


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Chart

Dr Reddy's Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 14.03 14.05 12.65

Dr Reddy's Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.68 12.65 11.71 13.37 12.69

Competitive Comparison of Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio falls into.



Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dr Reddy's Laboratories's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=4.243/153.2548*153.2548
=4.243

Current CPI (Dec. 2023) = 153.2548.

Dr Reddy's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 1.296 91.425 2.172
201406 1.285 94.103 2.093
201409 1.344 96.780 2.128
201412 1.579 96.780 2.500
201503 1.896 97.163 2.991
201506 1.786 99.841 2.742
201509 2.293 101.753 3.454
201512 2.256 102.901 3.360
201603 2.023 102.518 3.024
201606 1.614 105.961 2.334
201609 1.754 105.961 2.537
201612 1.841 105.196 2.682
201703 1.697 105.196 2.472
201706 1.702 107.109 2.435
201709 1.728 109.021 2.429
201712 1.958 109.404 2.743
201803 1.787 109.786 2.495
201806 2.076 111.317 2.858
201809 2.165 115.142 2.882
201812 2.118 115.142 2.819
201903 2.228 118.202 2.889
201906 2.143 120.880 2.717
201909 2.785 123.175 3.465
201912 2.543 126.235 3.087
202003 2.913 124.705 3.580
202006 3.036 127.000 3.664
202009 3.604 130.118 4.245
202012 3.451 130.889 4.041
202103 3.668 131.771 4.266
202106 3.371 134.084 3.853
202109 4.141 135.847 4.672
202112 3.998 138.161 4.435
202203 3.558 138.822 3.928
202206 3.378 142.347 3.637
202209 4.128 144.661 4.373
202212 4.313 145.763 4.535
202303 3.992 146.865 4.166
202306 3.981 150.280 4.060
202309 4.090 151.492 4.138
202312 4.243 153.255 4.243

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Dr Reddy's Laboratories  (BSP:R1DY34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=62.64/12.69
=4.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.89. The lowest was 2.27. And the median was 3.94.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Dr Reddy's Laboratories (BSP:R1DY34) Business Description

Address
8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (BSP:R1DY34) Headlines

No Headlines